Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Evaluation of the Long Term Safety and Efficacy of AAVAnc80-antiVEGF Gene Therapy in Individuals With Vestibular Schwannoma

NCT07503613 is registered in ClinicalTrials.gov with Akouos, Inc. as lead sponsor.

NCT NCT07503613
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07503613 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Evaluation of the Long Term Safety and Efficacy of AAVAnc80-antiVEGF Gene Therapy in Individuals With Vestibular Schwannoma
Lead sponsor
Akouos, Inc.
Phase
Observational
Overall status
Enrolling by invitation
Start date
March 2, 2026
Completion date
April 30, 2040
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

vestibular schwannoma